• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Grifols S.A.

    5/15/26 1:13:41 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRFS alert in real time by email
    6-K 1 tm2614775d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2026

     

    Commission File No. 001-35193

     

    Grifols, S.A.

    (Translation of registrant’s name into English)

     

     

    Avinguda de la Generalitat, 152-158

    Parc de Negocis Can Sant Joan

    Sant Cugat del Valles 08174

    Barcelona, Spain

    (Address of registrant’s principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F x                                          Form 40-F ¨

     

     

     

     

     

     

    Grifols, S.A.

     

    TABLE OF CONTENTS

     

    Item   Sequential Page Number
         
    1. Call for General Shareholders' Meeting, dated May 15, 2026 3

     

     

     

     

     

    Grifols, S.A.

     

    Avinguda de la Generalitat 152-158
    08174 Sant Cugat del Vallès
    Barcelona - SPAIN

     

    Tel. [34] 935 710 500
    Fax [34] 935 710 267

     

    www.grifols.com

     

    THIS DOCUMENT CONSTITUTES A TRANSLATION INTO ENGLISH OF THE OFFICIAL SPANISH VERSION. IN CASE OF DISCREPANCIES, THE OFFICIAL SPANISH VERSION SHALL PREVAIL.

     

    GRIFOLS, S.A.

     

    ORDINARY GENERAL SHAREHOLDERS' MEETING

     

    The Board of Directors has resolved to call the shareholders of Grifols, S.A. (the “Company”) to the Ordinary General Shareholders' Meeting that will be held on first call, at the Company's registered office, that is, Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158, 08174 Sant Cugat del Vallès, Barcelona, at 12:00 p.m. CET on June 17, 2026, and at the same place and time, on June 18, 2026, on second call.

     

    The Board of Directors has also resolved to approve the possibility to attend the Ordinary General Shareholders' Meeting by telematic means, by remote, simultaneous and bidirectional connection, in accordance with the provisions of the Articles of Association and the Regulations of the General Shareholders' Meeting of the Company.

     

    The General Shareholders' Meeting will be held in accordance with the following:

     

    Agenda

     

    First.Review and approval, as the case may be, of the individual annual accounts and management report, as well as the proposal for allocation of results relating to the fiscal year ended December 31, 2025, and approval of the distribution of the preferred dividend corresponding to Class B shares.

     

    Second.Review and approval, as the case may be, of the consolidated annual accounts and management report relating to the fiscal year ended December 31, 2025.

     

    Third.Review and approval, as the case may be, of the consolidated non-financial information statement and sustainability reporting of Grifols, S.A. and its subsidiaries, included in the consolidated management report relating to the fiscal year ended December 31, 2025.

     

    Fourth.Review and approval, as the case may be, of the performance of the Board of Directors throughout the fiscal year ended December 31, 2025.

     

    Fifth.Re-election of Deloitte Auditores, S.L. as statutory auditor of the Company and its consolidated group for fiscal years 2027, 2028 and 2029, inclusive.

     

    Sixth.Appointment of Deloitte Auditores, S.L. as the independent assurance services provider (verificador de la información sobre sostenibilidad) of the Company and its consolidated group to carry out the assurance of sustainability information (para realizar la verificación de la información sobre sostenibilidad) corresponding to fiscal year 2026.

     

    Seventh.Dismissal, resignation, re-election and/or appointment or ratification, if applicable, of the members of the Board of Directors. Amendment, if applicable, of the number of members of the Board of Directors:

     

    7.1Re-election of Ms. Montserrat Muñoz Abellana as a member of the Board of Directors.

     

     

     

     

     

     

    7.2Re-election of Ms. Susana González Rodríguez as a member of the Board of Directors.

     

    7.3Amendment, if applicable, of the number of members of the Board of Directors.

     

    Eighth.Information on the amendments of the Internal Regulations of the Company's Board of Directors, pursuant to article 528 of the Capital Companies Act.

     

    Ninth.Amendment of the directors' remuneration policy of the Company.

     

    Tenth.Consultative vote on the Annual Remuneration Report.

     

    Eleventh.Authorization to the Board of Directors to call, if necessary, Extraordinary General Shareholders' Meetings of the Company with at least 15 days in advance, in accordance with article 515 of the Capital Companies Act.

     

    Twelfth.Delegation to the Board of Directors, with full power of substitution in any of its members, of the authority to increase the Company's share capital pursuant to the provisions of article 297.1.b) of the Capital Companies Act, within the legal term of five years as of the date of this General Shareholders' Meeting, up to the maximum amount equivalent to 50% of the Company's share capital as of the date of this authorization, being enabled to carry out the increase at once or in several times. Pursuant to the provisions of article 506 of the Capital Companies Act, delegation to the Board of Directors, with full power of substitution in any of its members, of the authority to exclude the pre-emptive subscription rights in the relevant capital increases, up to the limit of 20% of the share capital. To revoke the resolution of delegation to the Board of Directors of the authority to increase the Company's share capital passed on May 21, 2021.

     

    Thirteenth.Renewal of the delegation to the Board of Directors, with the full power of substitution in any of its members, of the authority to apply for the listing of the Company’s ordinary Class A shares on NASDAQ. Revocation of the previous delegation of authorities passed by the Ordinary General Shareholders’ Meeting of June 16, 2023.

     

    Fourteenth.Authorization to the Board of Directors, with express power of substitution, for the derivative acquisition of treasury stock, revoking and leaving without effect the authorization agreed by the Ordinary General Shareholders' Meeting of June 5, 2025.

     

    Fifteenth.Approval of a reduction of the Company’s share capital, by an amount up to a maximum equal to 10% of the share capital as of the date of this resolution, to be implemented by means of the redemption of the Company’s treasury Class A and Class B shares, such reduction to affect both classes of shares equally and such that each Class B Share shall receive the same treatment as each Class A Share that has been acquired by the Company by way of derivative acquisition for the purpose of being redeemed. Delegation to the Board of Directors of all such powers as may be necessary to implement the foregoing share capital reduction, in whole or in part, on one or more occasions, or to refrain from carrying it out, and to determine the remaining terms and conditions of the share capital reduction in all matters not expressly resolved by the General Shareholders’ Meeting, including, among others, the power to amend the wording of Article 6 of the Company’s Articles of Association relating to the share capital, and to apply for the delisting from trading and the cancellation in the relevant book-entry records of the shares to be redeemed.

     

     

     

      

     

     

    Sixteenth.Granting of authorities to formalize and execute the resolutions passed by the General Shareholders' Meeting.

     

    It is stated that, pursuant to the provisions of the Company's Articles of Association, only the shareholders who hold Class A shares will have the right to vote on the items included in the agenda.

     

    Supplement to the call and filing of new resolution proposals

     

    Pursuant to the provisions of article 519 of the Capital Companies Act (Ley de Sociedades de Capital), shareholders representing at least three percent of the Company's share capital may request the publication of a supplement to this call, including one or more items on the agenda, and filing well-founded resolution proposals on matters already included or that should be included on the agenda, provided that the new items are duly justified or accompanied, as appropriate, by a substantiated resolution proposal. This right may be exercised by means of a verifiable notice that must be received at the registered office of the Company, within five days following the publication of this notice of call or, as the case may be, of the supplement to the call. Such notice must provide evidence of the identity of the shareholders exercising such right and the number of shares they currently hold, as well as the items that, as the case may be, should be included on the agenda, and must be accompanied by all relevant documents.

     

    Right to information

     

    As from the date hereof, any shareholder will have the right to examine at the registered office of the Company (Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158, 08174, Sant Cugat del Vallès, Barcelona), to look up on the corporate web page (www.grifols.com), and to obtain or request the immediate delivery of the following documents, free of charge:

     

    (i)Proposed resolutions corresponding to each of the items included on the agenda of the General Shareholders' Meeting;

     

    (ii)The Company's individual and consolidated annual accounts for the fiscal year ended on December 31, 2025, together with the corresponding management and audit reports (the consolidated management report includes the consolidated non-financial information statement and sustainability reporting of Grifols, S.A. and its subsidiaries, and with the corresponding verification report);

     

    (iii)The report issued by the Appointments and Remuneration Committee on the prior analysis of the Company's Board of Directors' required competences;

     

    (iv)The relevant report issued by the Board of Directors concerning the proposals for re-election of directors referred to in the seventh item of the agenda;

     

     

     

     

     

     

    (v)Professional profiles and biographies of the directors whose re-election is proposed to the General Shareholders' Meeting;

     

    (vi)Complete text of the amendments to the Internal Regulations of the Company's Board of Directors referred to in the eighth item of the agenda;

     

    (vii)The proposal of the amendment to the directors' remuneration policy referred to in the ninth item of the agenda and the relevant report issued by the Appointments and Remuneration Committee;

     

    (viii)The relevant report issued by the Board of Directors concerning the proposal for the delegation of the power to increase the share capital and exclude the pre-emptive subscription rights referred to in the twelfth item of the agenda, in accordance with articles 286 and 506 of the Capital Companies Act;

     

    (ix)The relevant report issued by the Board of Directors concerning the proposal for the share capital reduction referred to in the fifteenth item of the agenda, in accordance with articles 286 and 318 of the Capital Companies Act;

     

    (x)The annual corporate governance report for the fiscal year ended on December 31, 2025;

     

    (xi)The annual report on the directors' remuneration;

     

    (xii)Total number of shares and voting rights on the date on which the General Shareholders’ Meeting is called; and

     

    (xiii)The forms that will have to be used for distance voting and granting of representation.

     

    Furthermore, the following reports will be published on the Company's corporate web page:

     

    (i)Reports on the functioning of the Audit Committee and the Appointments and Remuneration Committee corresponding to fiscal year 2025;

     

    (ii)Report on the related-party transactions corresponding to fiscal year 2025 issued by the Audit Committee; and

     

    (iii)Report on the independence of the Company's external auditors corresponding to fiscal year 2025 issued by the Audit Committee.

     

    Additionally, pursuant to the provisions of articles 197, 272 and 520 of the Capital Companies Act (Ley de Sociedades de Capital), article 39 of the Regulations of the Board of Directors and article 9 of the Regulations of the General Shareholders' Meeting, the shareholders may request in writing that the Board of Directors, from the date of the publication of the notice of the call until the fifth day before the date when the General Shareholders' Meeting is to be held, or verbally while the meeting is being held, provide any information and clarifications that they may deem necessary, or raise any questions that they deem pertinent regarding the items included in the agenda. Furthermore, shareholders may request, within the same deadline and in the same form, any information or clarifications or raise any questions concerning the information accessible to the general public that has been provided by the Company to the National Securities Market Commission (Comisión Nacional del Mercado de Valores) since the last General Shareholders' Meeting (June 5, 2025) and concerning the auditor's report. Those shareholders (or their proxy representatives) who attend the General Shareholders' Meeting by telematic means may exercise this information right under the terms set forth in the corresponding section of this notice.

     

     

     

     

     

     

    Shareholders' Electronic Forum

     

    Pursuant to the provisions of article 539 of the Capital Companies Act (Ley de Sociedades de Capital), on occasion of the call of the General Shareholders' Meeting and until 8:30 a.m. CET of the same day it is held, the Company has enabled the Shareholders' Electronic Forum on the Company's corporate web page (www.grifols.com). The operating rules and the form that the shareholders must fill in in order to participate in said Forum are available on the Company's corporate web page.

     

    Right to attend

     

    All shareholders of the Company will have the right to attend the General Shareholders' Meeting, provided that their shares are registered under their name in the corresponding accounting registry at least five days prior to the day on which the General Shareholders' Meeting is to be held.

     

    In order to exercise the right to attend, the shareholder must have the relevant attendance card issued for such purposes by the entities responsible for the accounting registry.

     

    Any shareholder having the right to attend may be represented by another person, even if such person is not a shareholder. The representation shall be conferred on a special basis for this specific General Shareholders' Meeting, in writing or via any distance means of communication as set forth below.

     

    Those shareholders or proxy representatives that wish to attend to the General Shareholders' Meeting by telematic means must follow the instructions set forth further below.

     

    Right to vote and distance voting

     

    Shareholders may cast their vote regarding the proposals included on the agenda through the following distance means of communication:

     

    (a)by means of postal correspondence, by sending the attendance, delegation and distance voting card, duly signed and with an indication of the direction of their vote, to the following address: Grifols, S.A. (re: General Shareholders' Meeting), Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158, 08174, Sant Cugat del Vallès, Barcelona, Spain; and

     

    (b)by means of electronic communication, through the Company's corporate web page (www.grifols.com), provided that the security of the electronic communication is ensured, and the electronic document through which the vote is casted includes a qualified electronic signature, pursuant to the provisions of the Regulation (EU) No 910/2014 of 23 July, or is considered valid by the Board of Directors as it fulfils the adequate guarantees on authenticity and identity of the voting shareholder.

     

     

     

     

     

     

    Likewise, the shareholders entitled to attend may confer their representation, specifically for this General Shareholders' Meeting, by the following distance means of communication:

     

    (a)by means of postal correspondence, by sending the relevant card duly signed, including name and identity card of the shareholder being represented, to the following address: Grifols, S.A. (re: General Shareholders' Meeting), Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158, 08174, Sant Cugat del Vallès, Barcelona, Spain; and

     

    (b)by means of electronic communication, through the Company's corporate web page (www.grifols.com), provided that the security of electronic communications is ensured and that the electronic document through which the representation is formalized includes a qualified electronic signature, pursuant to the provisions of the Regulation (EU) No 910/2014 of 23 July, or is considered valid by the Board of Directors as it fulfils the guarantees on authenticity and identity of the voting shareholder conferring their representation.

     

    The shareholders who confer their representation by means of distance communication must notify the appointed proxy representative of the representation conferred. When the representation is conferred to a Board Member and/or the Secretary and/or the Vice Secretary of the Company, such communication will be deemed to be made upon receipt by the Company of the distance delegation.

     

    Distance delegations must be accepted by the proxy, not being able to join otherwise. For this purpose, all distance delegations in favor of individuals different than the Company's Board Members and/or Secretary and/or Vice Secretary must be printed out, signed and submitted by the proxy representatives who physically attend the General Shareholders' Meeting, together with an identity document, to the personnel in charge of the shareholders' registry on the date and place where the General Shareholders' Meeting is to be held, within the hour immediately prior to its scheduled start.

     

    Moreover, the delegation card duly completed and signed may also be submitted by the proxy representative physically attending the Meeting, together with an identity document, to the personnel in charge of the shareholders' registry, on the date and place where the General Shareholders' Meeting is to be held, within the hour immediately preceding its scheduled start.

     

    In order to be valid, both the vote and the distance delegation must be received by the Company at least before midnight (24:00) on the day prior to the date that the General Shareholders' Meeting is scheduled at its first call or second call, whichever is applicable.

     

    The Company reserves the right to modify, suspend, cancel or restrict the mechanisms for electronic voting and delegation for technical or security reasons. The Company further reserves the right to request such additional identification from the shareholders as may be deemed convenient in order to ensure the identity of those attending the meeting, the authenticity of the vote or the delegation and, in general, the legal certainty of the General

    Shareholders’ Meeting being held.

     

    The Company will not be liable for damages that may be caused to shareholders due to the lack of availability and effective operation of its corporate web page and of the services or contents provided through such web page as a result of any failure, overload, line failure, connection fault or similar events not attributable to the Company that may impede the use of the electronic voting or delegation systems.

     

     

     

     

     

     

    Computer applications for casting the vote and the delegation through electronic means will be operative from the day the call is published at 00:00:01 hours CET until June 17, 2026 at 23:59:59 hours CET.

     

    Attendance to the General Shareholders' Meeting by telematic means

     

    Notwithstanding the provisions set forth above and in accordance with article 182 of the Capital Companies Act (Ley de Sociedades de Capital) and article 16 of the Company's Articles of Association, the shareholders and their proxy representatives may attend the General Shareholders' Meeting by telematic means.

     

    1.             Registration, accreditation and attendance:

     

    In order to enable the proper management of the online attendance systems, the shareholder or proxy representative wishing to attend the General Shareholders' Meeting by telematic means must:

     

    (a)Register on the Online Attendance Platform enabled to such effect on the Company's corporate web page (www.grifols.com), providing proof of identity (and, where applicable, their representation) from June 12, 2026 at 00:00:01 hours CET until the day in which the General Shareholders' Meeting is to be held (i.e. June 17, 2026, on first call and if applicable, on the following day, June 18, 2026, on second call) at 11:00:00 hours CET through any of the following means: (i) Electronic National Identity Card; (ii) a qualified certificate for electronic signature valid and in force, in accordance with the Regulation (EU) No 910/2014 of 23 July, and issued by the Spanish Public Certification Authority (CERES) that answers to the Spanish National Mint (Fábrica Nacional de Moneda y Timbre); or (iii) by attaching a photocopy of his/her National Identity Card or a similar document providing his/her identity (Passport or NIE) in pdf format. In this latter case, once the proof of identity has been approved by the Company, the duly registered shareholder or proxy representative will receive a username and a password to access the General Shareholders' Meeting by telematic means.

     

    At the time of registration it is essential to provide proof of the status of shareholder, and, if appropriate, proxy representative, by attaching to the corresponding form a pdf copy of the duly signed attendance card issued by the participating entity of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores

    (Iberclear) where the shareholder's shares are deposited.

     

    Moreover, the shareholder that is a legal entity shall also attach to the corresponding form a pdf copy of the documents that prove the representative authorities of the natural person that represents it. In addition, the shareholder's proxy representative shall attach a copy of the document in which the representation is granted.

     

    Any registration made outside the deadlines indicated above or which does not comply with the accreditation requirements referred to in this section (a) will not be accepted.

     

    The Company reserves the right to request from the shareholders and/or its proxy representatives any additional proofs of identification it considers necessary to verify their status as shareholders or the sufficiency of the powers of representation granted.

     

     

     

     

     

     

    (b)Once the shareholder or its proxy representative is duly registered in accordance with section (a) above, he/she shall connect as an attendee by accessing the Online Attendance Platform enabled to such effect on the Company's corporate web page (www.grifols.com), on the day in which the General Shareholders' Meeting is to be held (i.e. June 17, 2026, on first call and if applicable, on the following day, June 18, 2026, on second call) between 10:00 and 12:00 hours CET, using the means indicated in the first paragraph of section (a) above. Once the Meeting has begun, only the shareholders and proxy representatives who have logged on the date and within the times indicated above will be able to vote and/or participate.

     

    2.             Exercise of the rights of intervention, information and proposal:

     

    The shareholders or their proxy representatives who, in exercise of their rights, wish to participate at the Meeting by telematic means and, if necessary, request information or clarifications regarding the items included on the agenda, the information accessible to the general public that has been provided by the Company to the National Securities Market Commission (Comisión Nacional del Mercado de Valores) since the last General Shareholders' Meeting or the auditor's report, or make proposals as permitted by Law, must submit their requests or proposals in writing by sending an electronic communication with their intervention (or attaching their written intervention) through the Online Attendance Platform enabled on the Company's web page. These rights may be exercised from the moment the shareholders or their proxy representatives are connected to the General Shareholders' Meeting via telematic means and until the closing of the period of interventions, which will be duly indicated during the course of the General Shareholders' Meeting.

     

    The attendee to the Meeting by telematic means who wishes to have his/her intervention expressly included in the minutes of the General Shareholders' Meeting must state this clearly and expressly within his/her written communication.

     

    The interventions of the attendees to the Meeting by telematic means can be verbally answered during the General Shareholders' Meeting or in writing within seven days thereafter, all in accordance with the provisions of the Capital Companies Act (Ley de Sociedades de Capital).

     

    3.             Voting:

     

    Votes may be cast by telematic means on the proposals relating to the items included on the agenda using the form available on the Online Attendance Platform enabled for this purpose on the Company's web page (www.grifols.com) from the time of their connection as attendees via telematic means on the date of the General Shareholders' Meeting indicated in section 1.(b) above, and until the moment the voting process on the proposed resolutions is concluded during the General Shareholders' Meeting, which will be indicated in due course during the General Shareholders' Meeting.

     

    With regard to the proposed resolutions on those matters not included on the agenda that have been presented in the legally admissible cases, those attending by telematic means may cast their vote through the form available on the Online Attendance Platform enabled for this purpose on the web page (www.grifols.com) from the moment these proposals are read out for voting and until the moment the voting process is concluded during the General Shareholders' Meeting.

     

     

     

     

     

     

    The rules on the computation of votes set out in the Articles of Association and in the Regulations of the General Shareholders' Meeting shall apply to the voting by telematic means.

     

    4.             Other issues:

     

    The shareholders or their proxy representatives who attend the General Shareholders' Meeting by telematic means and who wish to expressly state that they are abandoning the General Shareholders' Meeting so that their vote will not be counted, must do so by sending an electronic communication through the available link enabled for this purpose on the Online Attendance Platform on the Company's web page (www.grifols.com). Once such express desire to abandon the meeting has been communicated, all subsequent actions made by telematic means will be deemed as not having been carried out.

     

    The attendance by telematic means of the shareholder or his/her proxy representative will render void any vote or delegation previously made by any other procedure established by the Company.

     

    It is the exclusive responsibility of the shareholder or his/her proxy representative to maintain the passwords or any identification means required to access and use the Online Attendance Platform. In the case of a legal entity, it must notify any modification or revocation of the powers held by its representative and, therefore, the Company declines any responsibility until such notification takes place.

     

    The Company reserves the right to modify, suspend, cancel or restrict the mechanisms for the attendance to the General Shareholders' Meeting by telematic means when technical or security reasons so require or impose it. The Company will not be liable for damages that may be caused to shareholders as a result of any failure, overload, line failure, connection fault or similar events not attributable to the Company that may impede the use of the attendance systems to the General Shareholders' Meeting. Therefore, such circumstances will not constitute an illegitimate deprivation of the shareholders' rights. Should any of the circumstances envisaged in this section occur, the shareholders will be informed of this as soon as possible through the Company's web page.

     

    The rules for attendance at the General Shareholders' Meeting by telematic means adopted by the Board of Directors are available for the shareholders consultation on the Company's web page at www.grifols.com.

     

    Participation of a Notary at the Meeting

     

    The Board of Directors has resolved to request the presence of a Notary Public in order to draw up the minutes of the General Shareholders' Meeting, pursuant to the provisions of article 203 of the Capital Companies Act (Ley de Sociedades de Capital).

     

     

     

     

    Privacy Information

     

    Grifols, S.A. is the data controller responsible for processing your personal data for the purpose of managing the Shareholders’ Meeting. The legal basis for this processing is the management of the shareholder relationship, Grifols’ legitimate interest, and compliance with legal obligations. The information may be shared with the service providers that support the organization of the meeting. You may exercise your rights of access, rectification, and erasure, as well as other rights detailed in the additional information. You may review the detailed data protection information in the “Privacy Notices” section of the corporate website www.grifols.com (https://www.grifols.com/en/shareholders-meeting).

     

    The meeting will be streamed live to shareholders and/or authorized representatives, for the purpose of enabling them to follow the proceedings. The meeting will be audiovisually recorded to documenting the event. By entering the premises where the meeting is held or by making an intervention, the attendee’s image and voice may be captured for the purposes indicated, on the basis of the legitimate interest of Grifols, S.A.

     

    Expected date of the General Shareholders' Meeting

     

    THE SHAREHOLDERS ARE INFORMED THAT THE GENERAL SHAREHOLDERS' MEETING WILL FORESEEABLY BE HELD ON SECOND CALL ON JUNE 18, 2026 AT 12:00 HOURS CET, AT THE PLACE FIRST WRITTEN ABOVE.

     

    Attendance cards

     

    The shareholders are reminded that in order to exercise their right of attendance to the General Shareholders' Meeting they must have the relevant attendance card issued for such purposes by the entities responsible for the accounting registry. These attendance cards will have to detail, as applicable, the number of shares of each class (Class A or Class B shares) held by the shareholders. The entities in charge of the accounting registries may also issue to the shareholders two separate cards, that is, one for Class A shares and another for Class B shares held by each shareholder, as the case may be.

     

    Transport

     

    On June 18, 2026 the shareholders will have at their disposal a free shuttle service between the station of Sant Joan (Vallès line of the Catalan Railway Network – FGC) and the Company's offices where the General Shareholders' Meeting is to be held, running from 11:15 to 11:45 hours CET from the station, and from 13:15 hours CET from the Company's offices.

     

    Barcelona, May 15, 2026 

    The Secretary to the Board of Directors 

    Ms. Laura de la Cruz Galán

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

     

      Grifols, S.A.
         
      By: /s/ David I. Bell
        Name: David I. Bell
        Title: Authorized Signatory

     

    Date: May 15, 2026

     

     

     

    Get the next $GRFS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRFS

    DatePrice TargetRatingAnalyst
    2/12/2025Overweight
    Morgan Stanley
    3/12/2024Hold → Sell
    Deutsche Bank
    4/12/2023Equal-Weight → Overweight
    Morgan Stanley
    3/3/2023Overweight → Equal-Weight
    Morgan Stanley
    2/16/2023Underweight → Equal Weight
    Barclays
    1/18/2023Hold → Buy
    Jefferies
    4/8/2022Equal-Weight
    Morgan Stanley
    11/5/2021Buy → Hold
    Deutsche Bank
    More analyst ratings

    $GRFS
    SEC Filings

    View All

    SEC Form 6-K filed by Grifols S.A.

    6-K - Grifols SA (0001438569) (Filer)

    5/15/26 1:13:41 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Grifols S.A.

    SCHEDULE 13G/A - Grifols SA (0001438569) (Subject)

    5/14/26 4:05:28 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Grifols S.A.

    6-K - Grifols SA (0001438569) (Filer)

    5/7/26 2:35:37 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRFS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease

    Chronos‑PD shows that biological changes associated with Parkinson's disease (PD) can emerge up to 12 years before clinical diagnosisUncovered reproducible early molecular signals and distinct molecular patterns in PD, supporting future efforts in patient stratification and precision medicine researchChronos is part of a broad Grifols program to find early disease biomarkers leveraging more than 100 million proprietary plasma samples connected to real-world data on thousands of conditions Grifols presents data in 13 posters and oral presentations at AD/PD™ 2026 conference in Copenhagen (Denmark) BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS

    3/17/26 8:28:35 AM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

    Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the "Board") expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. The full text of the letter follows: May 28, 2025 Grifols, S.A. Avinguda de la Generalitat 152-158 0

    5/30/25 4:05:00 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

    ‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company's ongoing commitment to bold scientific innovation to benefit patients BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global

    1/14/25 6:00:00 AM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Grifols, S.A.

    Morgan Stanley resumed coverage of Grifols, S.A. with a rating of Overweight

    2/12/25 9:09:54 AM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grifols, S.A. downgraded by Deutsche Bank

    Deutsche Bank downgraded Grifols, S.A. from Hold to Sell

    3/12/24 1:36:28 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grifols, S.A. upgraded by Morgan Stanley

    Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight

    4/12/23 8:07:28 AM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRFS
    Financials

    Live finance-specific insights

    View All

    Grifols acquires its first plasma donation center in Canada

    BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers

    1/4/22 12:30:00 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRFS
    Leadership Updates

    Live Leadership Updates

    View All

    Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

    Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

    11/8/24 3:54:00 PM ET
    $GRFS
    $SYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

    BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

    4/18/23 10:30:00 AM ET
    $GRF
    $GRFS
    Finance/Investors Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

    Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)

    10/3/22 12:52:00 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Grifols S.A.

    SC 13G/A - Grifols SA (0001438569) (Subject)

    11/14/24 11:46:03 AM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Grifols S.A. (Amendment)

    SC 13G/A - Grifols SA (0001438569) (Subject)

    2/9/24 2:45:34 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grifols S.A.

    SC 13G - Grifols SA (0001438569) (Subject)

    2/9/24 2:21:17 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care